Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
90-Y-IMP-288
- Development stage
- Phase 2
- Lead developer
- CHU de Nantes
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
90-Y-IMP-288 is a radiolabeled peptide used in pretargeted radioimmunotherapy (PRIT) for cancer treatment. It consists of the synthetic hapten-peptide IMP-288 conjugated to the chelator DOTA and labeled with the beta-emitting radionuclide yttrium‑90 (Y‑90). The drug is designed for use in a two-step targeting strategy where a bispecific monoclonal antibody (such as TF10 or TF4) first binds to tumor-associated antigens and then captures the radiolabeled hapten-peptide at the tumor site. This approach delivers targeted cytotoxic radiation specifically to tumor cells expressing relevant antigens while minimizing exposure to normal tissues. Preclinical studies have shown efficacy in models of pancreatic cancer and B-cell lymphoma[1][3][4][6][8].
- Other names
- yttrium Y 90-DOTA-di-HSG peptide IMP-288IMP-288IMP288IMP 288
02
Targets
Histamine-succinyl-glycine hapten-binding paratopeMAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on 90-Y-IMP-288.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 90-Y-IMP-288.